ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER
- 1 December 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (6) , 1992-1995
- https://doi.org/10.1016/s0022-5347(05)66935-2
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- PSA decline is an independent prognostic marker in hormonally treated prostate cancer.European Urology, 1999
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- Combined androgen blockade for the treatment of metastatic cancer of the prostateUrology, 1996
- Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patientsThe Lancet, 1995
- Hormone refractory diseaseSeminars in Surgical Oncology, 1995
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Benefits of Combination Therapy with Flutamide in Patients Relapsing after CastrationBritish Journal of Urology, 1988
- Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experienceCancer and Metastasis Reviews, 1987
- Carcinoma of the prostate. Hormonal therapyCancer, 1987
- Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancerJournal of Steroid Biochemistry, 1986